GlassScriptPhysician profile
Adam D Falchook
NPI 1780773465
$292.49
in general payments reported to CMS, 2019-2025
12 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.42 · 2020: $88.75 · 2021: $64.32 · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $64.30 | 2019-2021 | |
| Mdd US Operations, LLC | $54.83 | 2020 | |
| Allergan, INC. | $33.92 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.55 | 2021 | |
| Lilly USA, LLC | $14.41 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.48 | 2021 |
5 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Falchook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.